White Paper

Navigating The Complex Realities Of Biomarker Testing In Oncology

Medical concept image Blood test GettyImages-1208340299

The move towards precision medicine within oncology has had drastic effects on the number of relevant biomarkers and their tests. According to IQVIA’s Oncology Dynamics database, on average, a cancer patient today gets tested for at least 1 predictive biomarker, with greater evolution of testing in certain indications, often with high incidence and high unmet need. Looking ahead, we see that the importance of biomarkers will increase, as more targeted products are launched, adding to the complexity observed in the oncology treatment environment today. 

The focus of this white paper is to highlight the rapidly evolving biomarker landscape in oncology from clinical development to regulatory uncertainties to commercial implications. It will focus on the key challenges and success factors involved in launching targeted therapies with biomarkers and/or in vitro diagnostics, outline how to navigate the complex realities of biomarkers and how the industry needs to adapt for targeted therapies to ultimately reach patients without creating too much of a burden on the healthcare system.

VIEW THE WHITE PAPER!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of ECM Connection? Subscribe today.

Subscribe to ECM Connection X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to ECM Connection

IQVIA Research & Development Solutions